Vaccination Reduces Anti-Nucleocapsid Seroconversion After Breakthrough SARS-CoV-2 Infection

In a randomized trial, 40% of mRNA-1273 recipients compared with >90% of placebo recipients developed anti-nucleocapsid antibodies.

Vaccination generates anti-spike but not anti-nucleocapsid (anti-N) antibodies; hence, anti-N antibodies are useful in sero-epidemiology studies, as endpoints in clinical trials, and to confirm the diagnosis of possible COVID-19 cases and COVID-19 inflammatory syndromes. The vast majority of SARS-CoV-2 infections in immune-naive individuals result in anti-N seroconversion, but in vaccinated populations, rates of seroconversion have not been well documented. Now, investigators report seroconversion rates among participants in the phase 3 mRNA-1273 (Moderna) clinical trial.

In all, 812 participants experienced proven SARS-CoV-2 infection ≥14 days after a second dose of mRNA-1273 or placebo. Seroconversion to anti-N occurred in 21/52 vaccinated…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Vaccination Reduces Anti-Nucleocapsid Seroconversion After Breakthrough SARS-CoV-2 Infection

Topics

Reviewing Author